EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Stiff-Soft Hybrid Biomimetic Nano-Emulsion for Targeted Liver Delivery and Treatment of Early Nonalcoholic Fatty Liver Disease

Juan Li, Mingxing Yin, Maoxian Tian, Jianguo Fang, Hanlin Xu iD

Pharmaceutics · 07.10.2024 · 16 (10) · 1303

DOI: 10.3390/pharmaceutics16101303 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 07.10.2024. Verfasst von Juan Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065, China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Nonalcoholic fatty liver disease (NAFLD) poses a risk for numerous metabolic diseases. To date, the U.S. Food and Drug Administration has not yet approved any medications for the treatment of NAFLD, for which developing therapeutic drugs is urgent. Dihydromyricetin (DMY), the most abundant flavonoid in vine tea, has been shown to be hepatoprotective. Its application was limited by low bioavailability in vivo; Methods: In order to improve the bioavailability of DMY and achieve liver-targeted delivery, we designed a DMY-loaded stiff-soft hybrid biomimetic nano drug delivery system (DMY-hNE). The in vivo absorption, distribution, pharmacokinetic profiles, and anti-NAFLD efficacy of DMY-hNE were studied; Results: DMY-hNE was composed of a stiff core and soft shell, which led to enhanced uptake by gastrointestinal epithelial cells and increased penetration of the mucus barrier, thus improving the in vivo absorption, plasma DMY concentration, and liver distribution versus free DMY. In an early NAFLD mouse model, DMY-hNE effectively ameliorated fatty lesions accompanied with reduced lipid levels and liver tissue inflammation; Conclusions: These findings suggested that DMY-hNE is a promising platform for liver drug delivery and treatment of hepatopathy.

Schlagwörter

Stichwörter der Autor:innen

biomimetic nano-emulsiondihydromyricetindrug delivery systemliver targetingnonalcoholic fatty liver disease

Autor:innen und Institutionen

  • School of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065, China.
  • Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.

ORCID-Profile: Hanlin Xu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Li, J., Yin, M., Tian, M., Fang, J., & Xu, H. (2024). Stiff-Soft Hybrid Biomimetic Nano-Emulsion for Targeted Liver Delivery and Treatment of Early Nonalcoholic Fatty Liver Disease. Pharmaceutics, 16(10), 1303. https://doi.org/10.3390/pharmaceutics16101303

Vancouver

Li J, Yin M, Tian M, Fang J, Xu H. Stiff-Soft Hybrid Biomimetic Nano-Emulsion for Targeted Liver Delivery and Treatment of Early Nonalcoholic Fatty Liver Disease. Pharmaceutics. 2024;16(10):1303. doi:10.3390/pharmaceutics16101303

BibTeX
@article{Li2024,
  author = {Li, Juan and Yin, Mingxing and Tian, Maoxian and Fang, Jianguo and Xu, Hanlin},
  title = {Stiff-Soft Hybrid Biomimetic Nano-Emulsion for Targeted Liver Delivery and Treatment of Early Nonalcoholic Fatty Liver Disease},
  journal = {Pharmaceutics},
  year = {2024},
  volume = {16},
  number = {10},
  pages = {1303},
  doi = {10.3390/pharmaceutics16101303}
}
Kostenlos starten →